2022-2023 Vaccine Recomendations

Generic Lab Tubes and Plates

2022-2023 WHO Northern Hemisphere recommendations

25 February 2022

It is recommended that quadrivalent vaccines for use in the 2022-2023 influenza season (Northern Hemisphere winter) contain the following:

Egg based vaccines:

  • an A/Victoria/2570/2019 (H1N1)pdm09-like virus
  • an A/Darwin/9/2021 (H3N2)-like virus;
  • a B/Austria/1359417/2021 (B/Victoria lineage)-like virus; and
  • a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.

    • Cell or recombinant based vaccines:

  • an A/Wisconsin/588/2019 (H1N1)pdm09-like virus;
  • an A/Darwin/6/2021 (H3N2)-like virus;
  • a B/Austria/1359417/2021 (B/Victoria lineage)-like virus; and
  • a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.

    • It is recommended that trivalent vaccines for use in the 2022-2023 influenza season (Northern Hemisphere winter) contain the following:

    Egg based vaccines:

  • an A/Victoria/2570/2019 (H1N1)pdm09-like virus
  • an A/Darwin/9/2021 (H3N2)-like virus; and
  • a B/Austria/1359417/2021(B/Victoria lineage)-like virus

    • Cell or recombinant based vaccines:

  • an A/Wisconsin/588/2019 (H1N1)pdm09-like virus;
  • an A/Darwin/6/2021 (H3N2)-like virus; and
  • a B/Austria/1359417/2021 (B/Victoria lineage)-like virus.

    • Full WHO Recommendation

    Top of Page

    AIVC recommendation for the composition of influenza vaccine for Australia in 2022

    7 October 2021

    The AIVC met on 6 October 2021 and recommended that the following viruses be used for influenza vaccines in the 2022 Southern Hemisphere influenza season:

    Egg based vaccines:

  • an A/Victoria/2570/2019 (H1N1)pdm09-like virus
  • an A/Darwin/9/2021 (H3N2)-like virus;
  • a B/Austria/1359417/2021 (B/Victoria lineage)-like virus; and
  • a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.

    • Cell or recombinant based vaccines:

  • an A/Wisconsin/588/2019 (H1N1)pdm09-like virus;
  • an A/Darwin/6/2021 (H3N2)-like virus;
  • a B/Austria/1359417/2021 (B/Victoria lineage)-like virus; and
  • a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.

    • The composition of trivalent influenza vaccines is recommended to include the H1N1, H3N2 and the B Victoria lineage virus.

    See the TGA website for further information

    Top of Page

    2022 WHO Southern Hemisphere recommendations

    24 September 2021

    It is recommended that quadrivalent vaccines for use in the 2022 influenza season (Southern Hemisphere winter) contain the following:

    Egg based vaccines:

  • an A/Victoria/2570/2019 (H1N1)pdm09-like virus
  • an A/Darwin/9/2021 (H3N2)-like virus;
  • a B/Austria/1359417/2021 (B/Victoria lineage)-like virus; and
  • a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.

    • Cell or recombinant based vaccines:

  • an A/Wisconsin/588/2019 (H1N1)pdm09-like virus;
  • an A/Darwin/6/2021 (H3N2)-like virus;
  • a B/Austria/1359417/2021 (B/Victoria lineage)-like virus; and
  • a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.

    • It is recommended that trivalent vaccines for use in the 2022 influenza season (Southern Hemisphere winter) contain the following:

    Egg based vaccines:

  • an A/Victoria/2570/2019 (H1N1)pdm09-like virus
  • an A/Darwin/9/2021 (H3N2)-like virus; and
  • a B/Austria/1359417/2021(B/Victoria lineage)-like virus

    • Cell or recombinant based vaccines:

  • an A/Wisconsin/588/2019 (H1N1)pdm09-like virus;
  • an A/Darwin/6/2021 (H3N2)-like virus; and
  • a B/Austria/1359417/2021 (B/Victoria lineage)-like virus.

    • Full WHO Recommendation

    Top of Page

    To view Recommendations from previous years, please click below: